Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2011 | 04:10am CET

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.

<Products for which distribution rights will be transferred>

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTELLAS PHARMA INC
11/16 ASTELLAS PHARMA : Findings from Astellas Pharma Yields New Findings on Medicinal..
11/16 SEATTLE GENETICS : and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in..
11/16 ASTELLAS PHARMA : Study Findings on Medicinal Chemistry Are Outlined in Reports ..
11/16 FINDINGS IN THE AREA OF PHARMACOLOGY : A novel highly...
11/16 ASTELLAS PHARMA : Study Findings from H.E. Burton et al Broaden Understanding of..
11/16 ASTELLAS PHARMA : New Central Nervous System Agents Findings from Astellas Pharm..
11/09 ASTELLAS PHARMA : Partners with CNBC for its Global Branding Campaign
11/09 SEATTLE GENETICS : and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in..
11/09 ASTELLAS PHARMA : and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Ved..
11/03 ASTELLAS PHARMA : and FibroGen Announce Positive Topline Results from First Japa..
More news
News from SeekingAlpha
11/09 YOUR DAILY PHARMA SCOOP : Valeant Remains Risky, Novartis's Kisqali, Tesaro Tumb..
11/08 Seattle Genetics and Astellas launch early-stage study of enfortumab vedotin ..
11/02 CMS issues final list of therapies facing expiration of pass-through status f..
10/31 Astellas Pharma, Inc. ADR 2017 Q2 - Results - Earnings Call Slides
10/31 Astellas Pharma reports 1H results
Financials ( JPY)
Sales 2018 1 287 B
EBIT 2018 220 B
Net income 2018 180 B
Finance 2018 391 B
Yield 2018 2,47%
P/E ratio 2018 16,50
P/E ratio 2019 15,26
EV / Sales 2018 2,04x
EV / Sales 2019 1,98x
Capitalization 3 020 B
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 1 553  JPY
Spread / Average Target 6,4%
EPS Revisions
Managers
NameTitle
Yoshihiko Hatanaka President, CEO & Representative Director
Chikashi Takeda Chief Financial Officer
Mitsunori Matsuda Senior Executive Officer & President-Technology
Yoshiro Miyokawa Representative Director & Executive Vice President
Hironobu Yasuda Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC-10.76%26 949
JOHNSON & JOHNSON19.78%370 740
NOVARTIS11.20%219 321
PFIZER8.90%210 830
ROCHE HOLDING LTD.-1.55%200 193
MERCK AND COMPANY-6.23%150 550